The estimated Net Worth of Thomas H Robinson is at least $202 mil dollars as of 13 June 2016. Mr. Robinson owns over 32,000 units of Biostage stock worth over $201,500 and over the last 8 years he sold BSTG stock worth over $0. In addition, he makes $0 as Independent Director at Biostage.
Thomas has made over 2 trades of the Biostage stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 32,000 units of BSTG stock worth $37,440 on 13 June 2016.
The largest trade he's ever made was buying 32,000 units of Biostage stock on 13 June 2016 worth over $37,440. On average, Thomas trades about 12,500 units every 6 days since 2016. As of 13 June 2016 he still owns at least 50,000 units of Biostage stock.
You can see the complete history of Mr. Robinson stock trades at the bottom of the page.
Thomas H. Robinson serves as an Independent Director of Harvard Apparatus Regenerative Technology Inc., Since September 2011, Mr. Robinson has served as a partner with RobinsonButler, an executive search firm. In 2010, Mr. Robinson served as managing director at Russell Reynolds Associates. From 1998 to 2010, Mr. Robinson served as managing partner of the North American medical technology practice, which includes the medical device, hospital supply/distribution and medical software areas, of Spencer Stuart, Inc., a global executive search firm. From 2002 to 2010, Mr. Robinson was a member of Spencer Stuart’s board services practice, which assists corporations to identify and recruit outside directors. From 1998 to 2000, Mr. Robinson headed Spencer Stuart’s North American biotechnology specialty practice. From 1993 to 1997, Mr. Robinson served as president of the emerging markets business at Boston Scientific Corporation, a global medical devices manufacturer. From 1991 to 1993, Mr. Robinson also served as president and chief operating officer of Brunswick Biomedical, a cardiology medical device company. Mr. Robinson currently serves on the Board of Directors of Cynosure, Inc. He received his M.B.A. from Harvard Business School and his B.A. in mathematics and economics from Brown University.
Thomas's mailing address filed with the SEC is C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746.
Over the last 8 years, insiders at Biostage have traded over $962,849 worth of Biostage stock and bought 1,593,581 units worth $3,804,230 . The most active insiders traders include David Green, Capital Llc Dst y Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of $217,604. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth $375,000.
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Biostage executives and other stock owners filed with the SEC include: